IntegenX Inc., a Pleasanton, CA-based company that designs, manufactures and markets automated DNA and RNA based sample preparation, has raised $15.6M in its second round of financing.
The round was led by Domain Associates, with participation from existing investors In-Q-Tel and RONAholdings LLC.
The company also acquired GenVault Corporation, a provider of biosample workflow, transport, and storage solutions for genomic medicine, discovery and identification. With the transaction, GenVault investors QuestMark Partners, Cross Creek Partners, and Greenspring Associates join the syndicate backing IntegenX.
The addition of GenVault’s products to the its portfolio allows IntegenX to offer products that will make transportation and storage of user samples easier without needing refrigeration and without allowing degradation. GenVault’s GenTegra™ products will increase the quality and value of data produced by IntegenX’s integrated sample preparation systems.
The capital will fund the commercialization of the Apollo 324 System for next-generation sequencing library preparation, the development of the Apollo 200 RapidHIT™ System for DNA-based human identification and the worldwide marketing of the GenVault’s GenTegra™ product line.
IntegenX is led by President and CEO Stevan Jovanovich, Ph.D.